CAR T-cell Therapy Articles

ODAC Unanimously Recommends Approval of Tisagenlecleucel for Pediatric ALL
Oncologic Drugs Advisory Committee voted 10-0 today to recommend approval of a biologics license application for tisagenlecleucel (CTL019) for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia.
Expert Discusses CD19 CAR T-Cell Therapy in B-Cell ALL

Eric Smith, MD, PhD, discusses the response to CD19 CAR T-cell therapy in B-cell ALL.
CTL019 CAR T-Cell Therapy Strides Towards Approval in Pediatric and Young Adult Patients With ALL
CTL019, an investigational chimeric antigen receptor T-cell therapy, demonstrated high response rates and a manageable safety profile in pediatric and young adult patients with relapsed and/or refractory acute lymphoblastic leukemia.
Response Rate Hits 100% for bb2121 in Multiple Myeloma
All patients with multiple myeloma in a phase I study showed a response following treatment with an active dose of bb2121, an investigational anti–BCMA CAR T-cell construct.
Biomarkers Emerge for Severe Neurotoxicity Risk After CAR T-Cell Therapy
Investigators reported the characterization of early clinical and serum biomarkers that may identify specific patients with ALL being treated with 19-28z chimeric antigen receptor T cells needing an early intervention to mitigate the development of severe neurotoxicity.
Expert Discusses State of CAR T-Cell Therapy in ALL
Bajil J. Shah, MD, discusses the significant impact CAR T-cell therapy can have on the treatment landscape for patients with acute lymphoblastic leukemia.
Marrow Clearance With Concurrent CAR T-Cells, Ibrutinib in Resistant CLL
Concurrent treatment with CTL-119 cell therapy and ibrutinib (Imbruvica) led to complete marrow clearance of leukemic cells in 8 of 9 evaluable patients with heavily pretreated or genetically high-risk chronic lymphocytic leukemia, results of a pilot study showed.
FDA Schedules ODAC Hearing for Tisagenlecleucel-T for Relapsed/Refractory B-cell ALL
The FDA’s Oncologic Drugs Advisory Committee has scheduled a public hearing to discuss a biologics license application for tisagenlecleucel-T for patients aged 3 to 25 years with relapsed/refractory B-cell acute lymphoblastic leukemia.
Expert  Explains Evolution of MCL Treatment
Peter Martin, MD, discusses the evolution of treatment and ongoing research for patients with mantle cell lymphoma.
FDA Grants Priority Review to KTE-C19 for Non-Hodgkin Lymphoma
The FDA has granted a priority review to axicabtagene ciloleucel for transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma.
Publication Bottom Border
Border Publication